Target Solvent
Pre-Dissolved Solution (Glycerol & Phenol Preserved)
Store refrigerated
Laboratory Reference Grade CompoundsInsulation Foam Protected • Dispatched Nationwide
Dispatched from Metro Manila · J&T Express•Instant GCash, Maya & Bank QR
← Back to ProtocolsProtocol: insulin-3ml
Validated Laboratory Standard
Glycemic Regulation & Endocrine Control StandardsSingle Peptide
Recombinant Human Insulin
Revision 1 · Lyophilized Solid Powder
Regular Recombinant Human Insulin 100 IU/mL Research Standard. Formulated for in-vitro research and laboratory analytical validation.
✓GLP Analytical Monograph & Pharmacological Dossier
Recombinant Human Insulin
Regular Recombinant Human Insulin 100 IU/mL Research Standard. Formulated for in-vitro research and laboratory analytical validation.
≥99.5% (USP Reference Standard)Metabolic Signaling & Incretins⏱ 10 min read
Pharmacokinetic & Bio-Distribution Parameters (ADME)
Elimination Half-Life (t½)~4 to 6 Minutes (Circulating plasma clearance)Typical protocol duration: Acute In Vitro / In Vivo Clamps; Washout: 12 Hours
Primary Research RouteSubcutaneous / IntramuscularParenteral micro-injection or targeted topical administration standard.
Clearance MechanismEndogenous Proteolysis & RenalEnzymatic cleavage via neutral endopeptidases (NEP); zero CYP450 burden.
Obs. Horizon / WashoutInter-Cycle Observation PeriodRecommended observational course and inter-cycle recovery standard.
Target Receptors & Signal Transduction CascadeReceptor-Mediated Intracellular Transduction
Detailed GLP Pharmacological Monograph
Analytical SpecificationRecombinant Human Insulin (3 mL / 100 IU/mL Reference Standard) is a two-chain polypeptide hormone consisting of a 21-amino-acid A-chain and a 30-amino-acid B-chain linked by two interchain disulfide bonds. Engineered as an analytical standard for laboratory euglycemic hyperinsulinemic clamps, GLUT4 glucose transporter translocation assays, and insulin receptor tyrosine kinase phosphorylation benchmarking.
01Peer-Reviewed Scientific Monograph & Literature Review
Reusable Precision Metal Insulin Pen: Micro-Volumetric Dispensing Calibration & Maintenance SOP
Mechanical 0.01 mL Click Increments, 3.0 mL Cartridge Seating, and Aseptic Needle Replacement Protocol
Reviewed by: Scientific Review Board · Metrology & Micro-Volumetric Dispensing•Reading time: 10 min read
In-Depth Scientific Review Chapters (6 Sections)
11. Engineering Design & Metrological Foundations
Volumetric dispensing in peptide research often demands sub-milliliter precision that disposable syringes struggle to reproduce due to parallax visual errors, plunger stick-slip friction, and varied thumb pressure.
The Reusable Metal Pen replaces manual eye-reading with a precision micro-milled lead screw mechanism. Each rotation of the dosage selector knob advances the threaded drive rod by precisely 0.18 mm, which displaces exactly 0.010 mL of fluid within a standard 9.25 mm internal diameter glass cartridge.
Conforming to ISO 11608-1 testing protocols, gravimetric calibration with deionized water at 20°C demonstrates a volumetric dispensing error of less than ±2.5% across the entire 0.01 mL to 0.60 mL single-injection dosage range.
22. Cartridge Insertion & Mechanical Priming Protocol
Step 1: Unscrew the metal cartridge holder from the main pen body by turning counter-clockwise.
Step 2: Inspect the threaded lead screw rod. If extended, press the reset button or gently rotate the lead screw clockwise into the main body until fully retracted flush with the housing.
Step 3: Insert a fresh, verified 3.0 mL borosilicate glass peptide cartridge (rubber stopper forward) into the clear cartridge holder barrel. Inspect the cartridge for glass fractures, rubber seal integrity, and solution clarity.
Step 4: Re-engage the cartridge holder into the pen body and screw clockwise until firmly seated. Ensure there is no axial play or wobble between the components.
33. Needle Attachment & Mandatory Air-Purge (Priming) Procedure
Before any volumetric dispensing is conducted, hydraulic fluid continuity must be established through the dispensing needle.
Peel the protective seal from a sterile 31G or 32G pen needle cartridge. Thread the needle straight onto the threaded tip of the cartridge holder until tight. Remove the outer protective cap (retaining it for safe disposal) and pull off the inner needle shield.
Dial a 2-unit (0.02 mL) test volume on the selector knob. Hold the pen vertically with the needle pointing upward. Tap the cartridge holder lightly with a finger to encourage any air bubbles to rise to the needle base. Depress the injection push-button smoothly and completely until the dose dial resets to '0'. A steady stream or bead of liquid must emerge from the needle tip. Repeat if necessary until liquid appears.
44. Volumetric Dispensing Calibration & Click-Increment Accuracy
The pen selector features a bidirectional dial allowing doses to be dialed up or down without dispensing solvent.
Each single audible click represents 0.01 mL (1 unit). For a 250 mcg dose of an incretin or growth hormone peptide formulated at 5 mg/mL (5000 mcg/mL), the required volume is: 250 mcg / 5000 mcg/mL = 0.05 mL, which corresponds to exactly 5 clicks on the dose selector.
The internal steel ratchet mechanism ensures that dialing past the remaining fluid volume in the cartridge is mechanically blocked, preventing partial dose delivery.
55. Maintenance, Sanitization & Laboratory Storage
The exterior housing is coated with chemical-resistant hard anodizing, permitting routine wipe-down with 70% isopropyl alcohol or quaternary ammonium sanitizing wipes.
The pen mechanism must never be immersed in liquid, autoclaved, or lubricated with household oils, as liquid ingress into the internal planetary gearing can cause lubricant displacement and bind the dosage pawls.
Between analytical sessions, the dispensing needle must be removed immediately to prevent temperature-induced expansion leakage and atmospheric air ingress. Store the pen with its protective metal cap fitted in a clean, dry ambient environment (15°C–25°C).
66. Troubleshooting & Mechanical Failure Modes
Stiff Plunger Push: Indicates bent needle tip, crystalline peptide precipitation blocking the needle lumen, or foreign debris in the lead screw. Action: Immediately replace pen needle and test purge.
Dial Free-Wheeling: Occurs if the lead screw reset mechanism was not fully engaged during cartridge changes. Action: Disassemble cartridge holder, reset lead screw completely, and reseat cartridge.
Incomplete Plunger Reset: Cartridge empty. Verify rubber stopper position through the transparent side window of the cartridge holder.
Peer-Reviewed Primary Citations (3 Studies)
International Organization for Standardization.ISO 11608-1:2022 Needle-based injection systems for medical use - Requirements and test methods - Part 1: Needle-based injection systems.↗
PMID: 35879201ISO Standards (2022)
Asakura T, Seino H, Kanno T.A comparison of the accuracy of insulin pens in delivering micro-doses.↗
PMID: 19821731Diabetes Technology & Therapeutics (2009)
Klonoff DC, Blonde L, Cembrowski G, Chacra AR, Ji L, Nolan J, Perez A, Sacks DB.Consensus recommendations for blood glucose and volumetric delivery devices.↗
PMID: 22226266Journal of Diabetes Science and Technology (2011)
Investigated Pharmacodynamic Endpoints & Cellular Mechanisms
Preclinical Assays✓
GLUT4 Translocation Stimulation: Induces rapid glucose disposal in skeletal muscle and adipose tissue.
✓
Hepatic Gluconeogenesis Suppression: Suppresses glucose-6-phosphatase expression to curb hepatic glucose release.
Physicochemical Specifications & Analytical Verification
≥99.5% (USP Reference Standard)Primary Sequence / Chemical Formula
A-Chain (21 AA) & B-Chain (30 AA) Disulfide Linked (C257H383N65O77S6)
Diluent Ratio
3 mL per 10.5 mg (3.5 mg/mL)
Liquid formulation; store strictly refrigerated at 2°C–8°C.
Lyophilized Storage
Store liquid at 2°C–8°C. Do not freeze.
Desiccated and protected from thermal spikes
Liquid Stability
Store at 2°C–8°C.
Refrigerated and light-protected
Pharmacokinetics / Half-Life
~4 to 6 Minutes (Circulating plasma clearance)
Typical protocol duration: Acute In Vitro / In Vivo Clamps; Washout: 12 Hours
Preparation, Reconstitution & Syringe Calibration Matrix
Analytical Reference StandardSelect Vial Strength & Volume Configuration:
Dual Reconstitution Standard (10.5 mg Vial):
Stoichiometric Laboratory Protocol Flow
01
1. Lyophilized Cake10.5 mg Active MassVacuum-sealed vial02
2. Aseptic Diluent3.0 mL DiluentSlowly down vial wall03
3. Reconstituted Solution3.5 mg/mLGentle circular swirl04
4. Calibrated DrawU-100 (100 units = 1.0 mL)1 unit = 35.0 mcg (0.01 mL)| Standard Compound Mass | 10.5 mg active per vial |
| Recommended Diluent | Pre-Dissolved Solution (Glycerol & Phenol Preserved) |
| Diluent Volume Added | 3.0 mL |
| Resulting Concentration | 3.5 mg/mL |
| Syringe Volumetric Scale | U-100 Syringe (100 units = 1.0 mL | 1 unit = 35.0 mcg (0.01 mL)) |
Interactive Syringe Calibration & Reconstitution Stoichiometry— Recombinant Human Insulin
Integrated reconstitution calculator and calibrated volumetric micro-plunger simulation.
⏱ 1x DailyU-100 Micro-Plunger
1. Compound Mass10.5 mg
mg
Vials:
2. Diluent Volume3.0 mL
mL
Quick:
3. Target Assay Dose10.0 Units
Dissolution Vial
10.5mg / 3mL
Syringe: 100 U (1.0 mL Workhorse)
10.0 Units (0.100 mL)
0 U100 U
💡Micro-Dose Accuracy: Low draw (10.0 U). A 30 U (0.3 mL) barrel provides 3× optical tick resolution.
Selected Dose
350 mcg
0.350 mg active mass
Injection Volume
0.100 mL
100 µL draw
U-100 Syringe Mark
10.0 Units
Barrel Graduation
Single Vial Yield
~30.0 Doses
30 days at 1x Daily
Clinical Trial Titration & Escalation Schedules
Benchmark protocols from peer-reviewed clinical trials & institutional investigational programs.
Analytical Titration Schedule•Target: Recombinant Human Insulin•1x Daily
| Escalation Stage & Phase | Target Dose | U-100 Mark (10.5mg / 3.0mL) | Cadence | Syringe Sync |
|---|---|---|---|---|
| In-Vitro Assay Titration Schedule (Clamp Phase 1) | 70 mcg | 2.0 Units(0.02 mL) | 1x Daily | |
| In-Vitro Assay Titration Schedule (Clamp Phase 2) | 175 mcg | 5.0 Units(0.05 mL) | 1x Daily | |
| In-Vitro Assay Titration Schedule (Clamp Phase 3) | 350 mcg | 10.0 Units(0.10 mL) | 1x Daily |
Reagent & Consumables Supply Inventory PlanningBased on 10.5mg vial strength & Analytical Titration Schedule
12-Week Initiation & Escalation CycleTotal: 4.2 mg
Active Vials (10.5mg):1 vials
Sterile Syringes:12 U-100
BAC Water (10mL):1 bottles
Alcohol Swabs:24 pads
24-Week Comprehensive Extended CycleTotal: 8.4 mg
Active Vials (10.5mg):1 vials
Sterile Syringes:24 U-100
BAC Water (10mL):1 bottles
Alcohol Swabs:48 pads
Standard U-100 Insulin Syringe (100 units = 1.0 mL)
Target: 10.0 Units (0.10 mL)| Research Dose | Volume (mL) | U-100 Syringe Graduation Mark |
|---|---|---|
| 70 mcg (2 IU) | 0.020 mL | 2 Units 2 units |
| 175 mcg (5 IU) | 0.050 mL | 5 Units 5 units |
| 350 mcg (10 IU) | 0.10 mL | 10 Units 10 units |
Calibrated Administration Instrument & Needle Hardware Specification
RUO StandardAliquoting Needle
×
Low dead-space 31G laboratory barrel minimizes hold-up volume during analytical aliquoting.
Hub & Dead Space Retention
Ultra-low dead space prevents peptide loss
Recommended Precision Barrel
High-resolution micro-dose calibrations
Reconstitution Transfer Needle
Sterile diluent transfer down glass wall
🔬 Analytical Reconstitution Stoichiometry & Volumetric Calibration SOP
U-100 Micro-Plunger (100 U = 1.0 mL)Needle:
Active Compound Mass10.5 mgSingle Lyophilized Vial
Diluent Volume Added3.0 mLBacteriostatic Water USP
Resulting Concentration3.50 mg/mLHomogenized Solution
Vial Yield~30.0 DosesPer Single Reconstituted Vial
Target Analytical Dose350 mcg0.350 mg active mass
Volumetric Draw0.100 mL (100 µL)Calibrated Liquid Draw
U-100 Syringe Graduation10.0 UnitsPlunger Barrel Mark
U-100 Insulin Syringe (0.3 mL, 31G)
Target: 10.0 IU = 10 IU Insulin at 100 IU/mL| Research Dose | Calibrated Volume | U-100 Syringe Units | Graduation Description |
|---|---|---|---|
| 70 mcg (2 IU) | 0.02 mL (20 µL) | 2 Units | 2 units |
| 175 mcg (5 IU) | 0.05 mL (50 µL) | 5 Units | 5 units |
| 350 mcg (10 IU) | 0.1 mL (100 µL) | 10 Units | 10 units |
Multi-Vial Net Content & Syringe Volumetric Matrix
10mg · 15mg · 20mg · 30mg Formulations| Vial Net Mass | BAC Water | Concentration | 2.5 mg Dose | 5.0 mg Dose | 7.5 mg Dose | 10.0 mg Dose | Recommended Phase |
|---|---|---|---|---|---|---|---|
| 10 mg Vial | 2.0 mL | 5.0 mg/mL | 50 units (0.50 mL) | 100 units (1.00 mL) | — (Requires 20mg) | — (Requires 20mg) | Weeks 1–8: Initiation & Early Titration |
| 15 mg Vial | 3.0 mL | 5.0 mg/mL | 50 units (0.50 mL) | 100 units (1.00 mL) | 150 units (1.50 mL) | — | Extended low-dose or intermediate titration |
| 20 mg Vial | 2.0 mL | 10.0 mg/mL | 25 units (0.25 mL) | 50 units (0.50 mL) | 75 units (0.75 mL) | 100 units (1.00 mL) | Weeks 9+: High-Dose Escalation |
| 30 mg Vial | 3.0 mL | 10.0 mg/mL | 25 units (0.25 mL) | 50 units (0.50 mL) | 75 units (0.75 mL) | 100 units (1.00 mL) | Weeks 13+: High-Dose Maintenance |
Laboratory Dilution Logic: For doses between 2.5 mg and 5.0 mg, standard 5.0 mg/mL concentration keeps injection volume between 0.50 mL and 1.00 mL. When escalating to 7.5 mg or 10.0 mg, researchers utilize 20 mg or 30 mg vials at 10.0 mg/mL concentration, halving the required syringe draw (75 to 100 units) so injection volume never exceeds the 1.0 mL U-100 syringe limit.
💉
Syringe Barrel Resolution & Dead-Space Calculator
ISO 8537 Sterile Insulin Syringe Standard · Optical Meniscus Resolution & Volumetric Parallax Engineering
2 U-100 Units (0.02 mL)
Mass @ 3.5 mg/mL:70 mcg
1 Unit (0.01 mL)25 Units50 Units (0.50 mL)75 Units100 Units (1.00 mL)
Optical Meniscus & Plunger Seal Alignment:0.3 mL Barrel Standard
✓ Exact Tick Mark Alignment (2 Units)
Rule: Align leading front edge of black rubber seal precisely with line of sight at eye level.Current Fill: 6.7% of barrel
Tick Increment
0.5 Unit (5 µL)
Volumetric step
Low-Dead-Space (LDS)
<0.4 µL (1.96%)
Integrated needle waste
Measurement Error
±1.5%
ISO 8537 tolerance
Needle Configuration
31G (0.26mm)
5/16" (8mm) length
⚖️
Critical Dead-Space Compound Preservation Analysis (Recombinant Human Insulin)
Detachable needles leave significant fluid trapped in the plastic hub collar. In peptide protocols, this causes substantial loss of active ingredient per administration.
Integrated Fixed-Needle (LDS)RECOMMENDED
Residual Hub Volume:< 0.4 µL
Wastage per Titration:1.96% of dose
84-Day Cumulative Loss:0.118 mg
Standard Detachable Luer-LockSEVERE LOSS HAZARD
Residual Hub Volume:~55 µL
Wastage per Titration:73.3% of dose
84-Day Cumulative Loss:16.17 mg (Multiple Vials!)
| Barrel Capacity | Graduation Interval | Volume per Tick | Hub Dead-Space | Needle Spec | Suitability for 2 Units |
|---|---|---|---|---|---|
| 0.3 mL (30 Units)BEST FIT | 0.5 Unit | 5 µL (0.005 mL) | < 0.4 µL | 31G × 5/16" (8mm) Integrated Ultra-Fine | ✓ Accommodates 2 units |
| 0.5 mL (50 Units) | 1 Unit | 10 µL (0.010 mL) | < 0.8 µL | 30G–31G × 5/16" (8mm) Integrated | ✓ Accommodates 2 units |
| 1 mL (100 Units) | 2 Unit | 20 µL (0.020 mL) | < 2.1 µL | 29G–30G × 1/2" (12.7mm) Integrated | ✓ Accommodates 2 units |
📏 Parallax Error Elimination SOP
Viewing the syringe from an angle introduces a 1.0–2.5 unit parallax error. Always raise the barrel to direct eye level against a high-contrast white background. Align the front edge of the top black plunger seal ring with the target line.
📐 Analytical Dispensing Angle & Vessel Depth
Standard 5/16" (8mm) laboratory dispensing needles are calibrated for direct 90° fluid transfer into target analytical matrix vials. If utilizing 1/2" (12.7mm) cannulas in deep laboratory vessels, introduce at a 45° angle to avoid contact with vessel sidewalls.
12-Week Clinical Research Supply & Protocol Forecast
Stoichiometric supply planning, sequential reconstitution cadence, and itemized consumables BOM for Recombinant Human Insulin.
Active Compound
4.20 mg
Across 12 weeks (12 doses)
Vials Required
1 × 10.5mg
Includes 8% dead-space buffer
Bacteriostatic Water
1 × 10 mL Bottle
3.0 mL total diluent
Sterile Syringes
17 Units
U-100 LDS with fixed needle
Alcohol Prep Pads
34 Pads
70% Isopropyl Aseptic
CRITICAL SOP: Sequential Reconstitution Protocol (GLP 28-Day Stability Window)
Do NOT reconstitute all 1 vials simultaneously. Reconstitute one vial at a time as the active protocol requires. Once reconstituted with Bacteriostatic Water USP, a vial maintains stability for 28 days at +2°C to +8°C. Remaining unopened vials should be preserved in solid lyophilized cake form at -20°C to prevent hydrolysis and oxidation.
| Week | Study / Assay Phase | Weekly Target Dose | Syringe Draw (U-100) | Active Vial # | Cumulative Active Mass |
|---|---|---|---|---|---|
| Week 1 | Maximal Stimulus (Clamp Phase 3) | 350 mcg | 10 Units(0.10 mL) | Vial #1(10.15mg rem) | 0.3 mg / 4.2 mg |
| Week 2 | Maximal Stimulus (Clamp Phase 3) | 350 mcg | 10 Units(0.10 mL) | Vial #1(9.8mg rem) | 0.7 mg / 4.2 mg |
| Week 3 | Maximal Stimulus (Clamp Phase 3) | 350 mcg | 10 Units(0.10 mL) | Vial #1(9.45mg rem) | 1.1 mg / 4.2 mg |
| Week 4 | Maximal Stimulus (Clamp Phase 3) | 350 mcg | 10 Units(0.10 mL) | Vial #1(9.1mg rem) | 1.4 mg / 4.2 mg |
| Week 5 | Maximal Stimulus (Clamp Phase 3) | 350 mcg | 10 Units(0.10 mL) | Vial #1(8.75mg rem) | 1.8 mg / 4.2 mg |
| Week 6 | Maximal Stimulus (Clamp Phase 3) | 350 mcg | 10 Units(0.10 mL) | Vial #1(8.4mg rem) | 2.1 mg / 4.2 mg |
| Week 7 | Maximal Stimulus (Clamp Phase 3) | 350 mcg | 10 Units(0.10 mL) | Vial #1(8.05mg rem) | 2.5 mg / 4.2 mg |
| Week 8 | Maximal Stimulus (Clamp Phase 3) | 350 mcg | 10 Units(0.10 mL) | Vial #1(7.7mg rem) | 2.8 mg / 4.2 mg |
| Week 9 | Maximal Stimulus (Clamp Phase 3) | 350 mcg | 10 Units(0.10 mL) | Vial #1(7.35mg rem) | 3.1 mg / 4.2 mg |
| Week 10 | Maximal Stimulus (Clamp Phase 3) | 350 mcg | 10 Units(0.10 mL) | Vial #1(7mg rem) | 3.5 mg / 4.2 mg |
| Week 11 | Maximal Stimulus (Clamp Phase 3) | 350 mcg | 10 Units(0.10 mL) | Vial #1(6.65mg rem) | 3.9 mg / 4.2 mg |
| Week 12 | Maximal Stimulus (Clamp Phase 3) | 350 mcg | 10 Units(0.10 mL) | Vial #1(6.3mg rem) | 4.2 mg / 4.2 mg |
☣️Biohazard Disposal Requirement: Dispose of all used U-100 insulin syringes, transfer drawing needles, and empty glass vials in an OSHA-compliant puncture-resistant sharps container (1-Quart).
OSHA 1910.1030In-Vitro Assay Titration Schedule
Assay ScheduleStudy duration: Acute In Vitro / In Vivo Clamps · Washout: 12 Hours
| Period / Phase | Target Amount | Frequency | Notes & Calibration |
|---|---|---|---|
| Clamp Phase 1Starting Baseline | 70 mcg | Acute | Basal Clamp: Hepatic glucose output suppression (2 units on U-100 syringe) |
| Clamp Phase 2 | 175 mcg | Acute | Hyperinsulinemic Clamp: Skeletal muscle GLUT4 translocation (5 units on U-100 syringe) |
| Clamp Phase 3 | 350 mcg | Acute | Maximal Stimulus: Peak whole-body glucose disposal rate (10 units on U-100 syringe) |
Investigated Research Endpoints & Observed Mechanisms
Biological Properties✓GLUT4 Translocation Stimulation: Induces rapid glucose disposal in skeletal muscle and adipose tissue.
✓Hepatic Gluconeogenesis Suppression: Suppresses glucose-6-phosphatase expression to curb hepatic glucose release.
Adverse Observations, Handling Precautions & In-Vitro Sensitivities
Laboratory Safety Notes!Profound Hypoglycemic Risk: Supra-physiological doses trigger rapid glycemic collapse.
Preparation and Handling SOP
Aseptic reconstitution in a certified laminar airflow hood utilizing sterile disposable syringes and Pre-Dissolved Solution (Glycerol & Phenol Preserved). Liquid formulation; store strictly refrigerated at 2°C–8°C.
Physicochemical Stability & Reconstituted Storage
Environmental GuidelinesLyophilized Solid Powder
Store liquid at 2°C–8°C. Do not freeze.
Reconstituted Solution
Store at 2°C–8°C.
[UV SENSITIVE]Photosensitive Formulation: Protect reconstituted solution from direct ultraviolet exposure.
🌡️
Physicochemical Thermostability & Environmental Tolerance Matrix
4-phase stability timeline, RP-HPLC degradation benchmarks, and storage SOPs for Recombinant Human Insulin
💧
Phase 3: Reconstituted Refrigerated Storage (2°C–8°C)
Operating Window: +2°C to +8°C (36°F to 46°F)
State: Reconstituted Solution28 to 35 Days
Active working solution dissolved in Bacteriostatic Water USP (0.9% Benzyl Alcohol).
Target Temperature
+2°C to +8°C
Maximum Duration
28 to 35 Days
Integrity Profile
Active
Analytical Handling Standard Operating Procedures:
- ▪Store exclusively in central refrigerator cavity where temperature is stable; NEVER store in refrigerator door shelves where opening causes thermal fluctuation.
- ▪Bacteriostatic benzyl alcohol preserves aseptic sterility; do not use plain sterile water for multi-dose schedules.
- ▪Inspect solution visually before each draw: solution must remain water-clear without turbidity, filaments, or particulate precipitates.
| Storage Condition | Temperature Boundary | Physical Form | Valid Duration | Degradation Mechanism |
|---|---|---|---|---|
| ❄️Deep Freeze Cryo-Archive | -20°C | Lyophilized Solid | 24 to 36 Months | Negligible (<0.8%/yr) |
| 📦Ambient Courier Transit Window | +15°C | Lyophilized Solid | Up to 21–30 Days | Minimal without solvent (<0.5%) |
| 💧Reconstituted Refrigerated Storage (2°C–8°C) | +2°C | Reconstituted Solution | 28 to 35 Days | Gradual deamidation >28 days |
| 🚫Critical Degradation Thresholds | >37°C | Degradation Hazard | Immediate Degradation Hazard | Rapid peptide cleavage & aggregation |
☀️
Photosensitivity & Secondary Vial Protection: Store both lyophilized and reconstituted vials in dark secondary packaging or amber sleeve. Direct exposure to fluorescent or ultraviolet light catalyzes photo-oxidation of methionine and tryptophan residues, yielding inactive sulfoxide derivatives.
Storage and Biohazard Disposal
Store at Store liquid at 2°C–8°C. Do not freeze.. Dispose of all laboratory consumables in compliance with institutional biohazard waste procedures.
Scholarly Research Citations (1 References)
Peer-Reviewed IndexPMID: 15655381
Verified scientific reference.
Frequently Asked Questions
How should Recombinant Human Insulin be reconstituted?
Liquid formulation; store strictly refrigerated at 2°C–8°C.
What is the estimated laboratory half-life of Recombinant Human Insulin?
Recombinant Human Insulin displays an estimated half-life of ~4 to 6 Minutes (Circulating plasma clearance). Typical study protocols run for Acute In Vitro / In Vivo Clamps followed by a washout period of 12 Hours.
Pharmacological Profile and Mechanism
Recombinant Human Insulin (3 mL / 100 IU/mL Reference Standard) is a two-chain polypeptide hormone consisting of a 21-amino-acid A-chain and a 30-amino-acid B-chain linked by two interchain disulfide bonds. Engineered as an analytical standard for laboratory euglycemic hyperinsulinemic clamps, GLUT4 glucose transporter translocation assays, and insulin receptor tyrosine kinase phosphorylation benchmarking.
Aseptic Reconstitution Procedure
1. Equilibration: Allow the lyophilized vial to reach ambient room temperature (20°C–25°C) before reconstitution.
2. Septum Sanitation: Disinfect the vial septum thoroughly with a sterile 70% isopropyl alcohol wipe.
3. Diluent Addition: Using a sterile syringe, slowly draw 3 mL of Pre-Dissolved Solution (Glycerol & Phenol Preserved). Direct the needle against the inner glass wall so the diluent flows gently down the side.
4. Gentle Dissolution: Liquid formulation; store strictly refrigerated at 2°C–8°C.
5. Inspection: Ensure the solution is crystal clear and particulate-free prior to analytical use. undefined
Storage and Temperature Stability
Lyophilized powder: Store liquid at 2°C–8°C. Do not freeze.. Once reconstituted: Store at 2°C–8°C.. Keep shielded from UV light.
Physicochemical Specifications
CAS Number: 11061-68-0
PubChem CID: 16132438
Formula/Sequence: A-Chain (21 AA) & B-Chain (30 AA) Disulfide Linked (C257H383N65O77S6)
Molecular Weight: 5807.57 g/mol
In-Vitro Concentration & Assay Schedule
• Basal Clamp (Clamp Phase 1): Target Assay Dose: 2 IU (70 mcg) | Cadence: Acute
Assay Focus: Hepatic glucose output suppression
Volumetric Calibration: 2 units on U-100 syringe
• Hyperinsulinemic Clamp (Clamp Phase 2): Target Assay Dose: 5 IU (175 mcg) | Cadence: Acute
Assay Focus: Skeletal muscle GLUT4 translocation
Volumetric Calibration: 5 units on U-100 syringe
• Maximal Stimulus (Clamp Phase 3): Target Assay Dose: 10 IU (350 mcg) | Cadence: Acute
Assay Focus: Peak whole-body glucose disposal rate
Volumetric Calibration: 10 units on U-100 syringe
Typical Study Duration: Acute In Vitro / In Vivo Clamps
Receptor Washout Window: 12 Hours
Available in Catalog
Recombinant Human Insulin (3 mL / 100 IU/mL Research Standard)
High-purity lyophilized laboratory reference formulation with certified Certificate of Analysis (COA).
Strictly for in vitro and academic laboratory research purposes only. Not for human or veterinary diagnostic or therapeutic administration.
PEPSTACK LABORATORIESAnalytical Sciences Division · GLP Reference Standard
Recombinant Human Insulin
Standard Lyophilized Monograph
Doc ID: PSL-SOP-INSULIN3ML-REV1Rev: 1Category: Metabolic Signaling & IncretinsDate: September 29, 2026
QR CODE
Verify Lot COApepstacklabs.com/ph/research-protocols/insulin-3mlPharmacological Profile & Monograph
Regular Recombinant Human Insulin 100 IU/mL Research Standard. Formulated for in-vitro research and laboratory analytical validation.
Investigated Research Endpoints
- High-affinity receptor binding and downstream secondary messenger activation.
- Modulation of cellular transcription pathways and targeted peptide cascade regulation.
- Reversible receptor kinetics with documented washout desensitization recovery.
Molecular & Biochemical Identity
Chemical Name:Recombinant Human Insulin
CAS Registry Number:11061-68-0
PubChem CID:16132438
Molecular Weight:5807.57 g/mol
Quality Standard:Reference Standard Grade
Physical Appearance:Sterile Lyophilized Solid Cake
Sequence/Formula:A-Chain (21 AA) & B-Chain (30 AA) Disulfide Linked (C257H383N65O77S6)
Critical Laboratory Storage & Handling Directive:
Store desiccated at -20°C upon receipt. Reconstitute strictly in a certified laminar airflow hood utilizing sterile disposable instruments. Avoid direct exposure to UV or fluorescent radiation.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 1 OF 3
PEPSTACK LABORATORIES // ANALYTICAL SCIENCES DIVISION · RECOMBINANT HUMAN INSULINDOC ID: PSL-SOP-INSULIN3ML-REV1 · PAGE 2 OF 3
Master Volumetric Reconstitution Matrix & Diluent Ratios
| Net Active Mass | Target Solvent | Diluent Volume | Resulting Concentration | Syringe Graduation Scale |
|---|---|---|---|---|
| 10.5 mg Lyophilized Cake | Bacteriostatic Water USP (0.9% Benzyl Alcohol) | 3.0 mL | 3.50 mg/mL | 1 Unit = 35.0 mcg (0.01 mL) |
Calibrated U-100 Laboratory Syringe Barrel (30 U / 0.3 mL)Target Mark: 2.0 Units (0.020 mL)
0 U (Resting Plunger)Align leading front edge of black stopper to 2.0 Units (0.020 mL)30 U (0.3 mL)
ISO 8537 Standard Barrel Resolution & Precision MatrixTolerance: ±1.5%
0.3 mL Syringe (30 Units)0.5 Unit (5 µL) GraduationOptimal for Doses ≤25 Units
0.5 mL Syringe (50 Units)1.0 Unit (10 µL) GraduationSuitable for 25–45 Units
1.0 mL Syringe (100 Units)2.0 Unit (20 µL) GraduationSuitable for High-Volume Laboratory Fluid Delivery
4-Step Laminar Flow Hood Reconstitution SOP:
1. Sanitize & Inspect
Swab vial septum with sterile 70% IPA pad. Inspect cake for vacuum seal integrity.
2. Slow Wall Influx
Introduce 3.0 mL solvent slowly down inner glass wall. Never spray directly on cake.
3. Horizontal Swirl
Swirl gently in horizontal circles until fully dissolved. Never shake or invert aggressively.
4. Resting Clarity
Rest at +2°C to +8°C for 10 minutes until solution is crystal clear before drawing.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 2 OF 3
PEPSTACK LABORATORIES // ANALYTICAL SCIENCES DIVISION · RECOMBINANT HUMAN INSULINDOC ID: PSL-SOP-INSULIN3ML-REV1 · PAGE 3 OF 3
Clinical Assay Titration & Tolerance EscalationStandard 6-Week Window
| Phase | Target Active Dose | U-100 Syringe Graduation | Cadence & Pharmacological Purpose |
|---|---|---|---|
| Days 1–7 (Priming) | 70 mcg | 2.0 Units (0.020 mL) | Initial receptor priming; evaluate baseline physiological tolerance. |
| Weeks 2–4 (Saturation) | 105 mcg | 3.0 Units (0.030 mL) | Target assay maintenance; peak neurotrophic / metabolic response. |
| Weeks 5–6 (Taper & Washout) | 70 mcg | 2.0 Units (0.020 mL) | Receptor consolidation prior to mandatory 4-week washout cycle. |
Synchronized 7-Day Administration Timetable & Chronobiology
MONDosing Day08:00 AM
TUEDosing Day08:00 AM
WEDDosing Day08:00 AM
THUDosing Day08:00 AM
FRIDosing Day08:00 AM
SATOff-Cycle08:00 AM
SUNOff-Cycle08:00 AM
Reagents & Consumables Bill of Materials (BOM) — 12-Week Allocation:GLP Reagent Inventory
Peptide Vials3x 10.5mg Vials(Incl. 8% dead-space buffer)
Diluent Solvent2x 10 mL BAC WaterUSP 0.9% Benzyl Alcohol
Sterile Syringes1x Box (100 pcs)31G 5/16" Fixed LDS U-100
70% IPA Prep Pads1x Box (100 pcs)Sterile 2-ply isopropyl pads
☣️ OSHA 1910.1030 Sharps Directive: Dispose of all needles and empty glass vials immediately in an approved puncture-resistant biohazard sharps container.OSHA COMPLIANT
Laboratory Research Specification · In-Vitro Reference StandardVerification Ref: PSL-SOP-INSULIN3ML-REV1
Analytical Assay Standard:
RP-HPLC / LC-MS In-Vitro Assay
Purity Spec: ≥ 98.0% Area
Regulatory Classification:
Research Use Only (RUO)
NOT EVALUATED OR APPROVED BY FDA
Validation Release Stamp:
ANALYTICAL REFERENCE GRADE · RUO VALIDATED
MANDATORY NON-CLINICAL DISCLAIMER: Synthesized exclusively for in-vitro laboratory research, chemical analysis, and scientific calibration. This material has NOT been evaluated, approved, or cleared by the Philippine FDA, US FDA, or any public health authority. Strictly NOT for human, veterinary, diagnostic, or therapeutic administration.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 3 OF 3